Cost-Effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
JAMA Neurol 2022 May 01;79(5)478-487, EL Ross, MS Weinberg, SE ArnoldFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.